Patients interested in checking their initial eligibility can use the BMI calculator before scheduling their first appointment
For people with type 2 diabetes, semaglutide has also shown significant improvements in A1C levels, reduced insulin resistance, and lower cardiovascular risk
These findings suggest that semaglutide protects against A-induced neurotoxicity by promoting autophagy and suppressing apoptosis
This is particularly noteworthy because two competing oral small-molecule GLP-1 programs from Pfizer, lotiglipron (discontinued in 2023) and danuglipron (discontinued in April 2025), were terminated due to liver toxicity concerns
The risk of hypoglycemia was low, and the most common adverse events were gastrointestinal, with nausea and diarrhea generally being the most frequently reported manifestations
Look for an email requesting your medical history information, consent for treatment and financial consent required to complete your consultation